Abstract
Candida auris is an emerging pathogen characterized for its difficult identification, rapid nosocomial spread, and limited treatment options. Data is currently limited; however, this will change as the pathogen’s prevalence increases. The goal of this review is to provide a concise summary of the available data to manage a possible C. auris infection. Candida auris has been rapidly spreading globally and has been evading popular identification methods with MALDI-TOF being the only successful modality as long as the “research use only” database is used. Echinocandins are the treatment of choice; however, all isolates should have susceptibilities performed as there have been reports of resistance to all antifungal classes. Several hospital outbreaks have occurred; thus, all patients should be isolated with appropriate terminal cleaning. Atypical or suspicious Candida isolates should be identified by MALDI-TOF. Most Candida auris strains are resistant to azoles; therefore, the suggested empirical treatment is an echinocandin. Echinocandin-resistant strains have been reported, and in those cases, a polyene is preferred. Strict contact precautions are recommended while in the hospital due to high levels of nosocomial transmission.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call